234 related articles for article (PubMed ID: 26066403)
1. Long-term Exposure to Testosterone Therapy and the Risk of High Grade Prostate Cancer.
Baillargeon J; Kuo YF; Fang X; Shahinian VB
J Urol; 2015 Dec; 194(6):1612-6. PubMed ID: 26066403
[TBL] [Abstract][Full Text] [Related]
2. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Kaplan AL; Hu JC
Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
5. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.
Wallis CJ; Lo K; Lee Y; Krakowsky Y; Garbens A; Satkunasivam R; Herschorn S; Kodama RT; Cheung P; Narod SA; Nam RK
Lancet Diabetes Endocrinol; 2016 Jun; 4(6):498-506. PubMed ID: 27165609
[TBL] [Abstract][Full Text] [Related]
6. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.
Klap J; Schmid M; Loughlin KR
J Urol; 2015 Feb; 193(2):403-13. PubMed ID: 25260832
[TBL] [Abstract][Full Text] [Related]
7. Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.
Lopez DS; Polychronopoulou E; Tsilidis KK; Khera M; Su LJ; Fowke JH; Peek MK; Kuo YF; Markides K; Canfield S
Cancer Prev Res (Phila); 2021 Jul; 14(7):719-728. PubMed ID: 33879532
[TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement therapy and prostate risks: where's the beef?
Morgentaler A
Can J Urol; 2006 Feb; 13 Suppl 1():40-3. PubMed ID: 16526980
[TBL] [Abstract][Full Text] [Related]
9. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
Morgunov LIu; Vertkin AL; Pushkar' DIu
Urologiia; 2007; (5):49-51. PubMed ID: 18254226
[TBL] [Abstract][Full Text] [Related]
10. [Testosterone and the prostate].
Sperling H; Rossi R; Lümmen G; Rübben H
Urologe A; 2004 Sep; 43(9):1092-6. PubMed ID: 15368045
[TBL] [Abstract][Full Text] [Related]
11. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
Shoskes DA; Barazani Y; Fareed K; Sabanegh E
Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
[TBL] [Abstract][Full Text] [Related]
13. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
[TBL] [Abstract][Full Text] [Related]
14. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
15. The effect of androgen supplementation therapy on the prostate.
Kaufman JM
Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
[TBL] [Abstract][Full Text] [Related]
16. Testosterone therapy and prostate cancer--safety concerns are well founded.
Klotz L
Nat Rev Urol; 2015 Jan; 12(1):48-54. PubMed ID: 25563848
[TBL] [Abstract][Full Text] [Related]
17. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
18. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
[TBL] [Abstract][Full Text] [Related]
19. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
20. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]